Turning Point Brands Cuts EBITDA Outlook Ceiling, Names Glazek CEO

Key Facts

Turning Point Brands named Executive Chairman David Glazek to succeed Graham Purdy as chief executive and, in the same announcement, cut the top end of its 2026 EBITDA outlook to $80 million from $90 million while retaining the $70 million floor. TPB closed at $60.12 on September 24, 2026, according to EL7 data. The announcement combines a leadership change with a narrower operating earnings forecast, both relevant to investors estimating future profits. The guidance revision also lowers the upper bound available for investors' valuation estimates. Glazek is scheduled to take charge after Purdy's service ends, under the timetable announced by the company.

TPB closed at $60.28 on September 22, 2026, then $60.50 on September 23, before falling to $60.12 on September 24, according to EL7 data. During the September 24 session, the stock ranged from $58.57 to $61.36, leaving its close above the day's low and below its high. Those dated figures matter when describing the decline: the September 24 close was below the previous close but above the session's lowest trade. The price sequence alone cannot allocate the move between the management change and the earnings revision. It is therefore best read alongside both developments disclosed in the company's announcement.

The company's previous 2026 EBITDA range was $70 million to $90 million; its revised range is $70 million to $80 million. That removes $10 million from the ceiling without changing the floor. The change matters for TPB's valuation because EBITDA is an operating earnings measure investors use when assessing a business's capacity to generate cash, although it is not itself cash flow. If the potential earnings ceiling falls while expected sales hold steady, margins and costs become more important in explaining future results. The company linked the narrower range to persistently higher freight costs and an assumption that bringing manufacturing onshore would yield no margin benefit until 2027.

Turning Point Brands maintained its 2026 Modern Oral gross sales forecast at $330 million to $350 million and its net sales forecast at $260 million to $270 million. The distinction matters because gross and net sales are different measures, and both forecast ranges stayed in place despite the lower EBITDA ceiling. If sales arrive within those ranges but earnings are weaker, the explanation will lie in the cost of serving that demand or the timing of manufacturing savings. The financial test is how much profit growth produces, rather than growth alone. The sales outlook remains intact, while the profitability of those sales has become more consequential for the stock's valuation.

Purdy's resignation takes effect September 30, 2026, and Glazek is due to become chief executive October 1, 2026. Glazek has been executive chairman since 2023 and a director since 2012, so the incoming chief executive already has a role in overseeing the business. The company attributed Purdy's departure to personal reasons and said it was unrelated to a disagreement with the company or its board. Naming a successor with a defined start date reduces the risk of an unfilled chief executive role, but does not settle how operating decisions will develop after the handover. For shareholders, continuity in executing the Modern Oral plan can be assessed through performance under Glazek.

Second-quarter 2026 results show the scale of the Modern Oral opportunity: Turning Point Brands' consolidated net sales rose 22.6% to $142.9 million. Modern Oral net sales reached $68.4 million, up 128% from a year earlier. The category accounted for 48% of company net sales, compared with 26% in the prior-year quarter. That comparison shows the faster-growing business has become a larger share of revenue, making the cost of supporting it more important to the company's earnings. As these products take more of the sales mix, the question is whether their growth can produce durable profit after the spending required to expand distribution.

The segment breakdown shows that second-quarter 2026 revenue growth was uneven across the business. Stoker's segment net sales rose 54.5% from a year earlier to $107.6 million, driven by Modern Oral growth. By contrast, Zig-Zag segment net sales fell 24.8% from the prior-year quarter. That divergence makes Modern Oral more influential in the direction of consolidated sales and places more weight on the segment that contains it when assessing growth. It also shows why companywide sales growth alone does not establish how every business performed or how stable the sources of profit are.

Sales growth did not bring comparable profit growth in the second quarter of 2026: adjusted EBITDA fell 50.0% to $15.2 million, and net income dropped 75.2% to $3.6 million. Selling, general and administrative expenses rose 91.1% to $76.9 million in the same period, including Modern Oral marketing investment and higher outbound freight costs. The company reported gross profit of $93.7 million, but said the figure was $81.5 million after adjusting for an out-of-period tariff refund effect. The gap between sales and earnings explains why investors need to follow the cost of building distribution and promotion as well as demand for the products. The accounting effect also matters when judging the level of profit that might persist in later periods.

Oppenheimer lowered its TPB price target to $90 from $130, according to a report by The Fly, while keeping an Outperform rating. A price target is an analyst's estimate of potential value, not a price the company or market has promised to deliver. It also differs from the stock's $60.12 closing price on September 24, 2026, according to EL7 data, and from the company's own operating forecasts. Keeping the rating while cutting the target indicates that the analyst changed the estimated level of potential value without changing the stock's classification. An investment decision still depends on the likelihood of the projected earnings and margins, rather than on the target alone.

The next transition date is October 1, 2026, when Glazek is due to become chief executive after Purdy's service ends September 30. The operating test will be whether the company delivers within its revised 2026 EBITDA range of $70 million to $80 million while meeting Modern Oral gross sales guidance of $330 million to $350 million and net sales guidance of $260 million to $270 million. If freight remains costly and onshoring brings no margin benefit before 2027, margins will remain central to valuation even if sales grow. Better profitability alongside targeted sales would give investors stronger evidence that the expanding business can support company earnings. Coming results will show whether the new earnings range holds or requires another revision.